Effect of tranexamic acid on progress of experimental tumours and on DNA-synthesis
- 1 June 1980
- journal article
- research article
- Published by Springer Nature in Cellular and Molecular Life Sciences
- Vol. 36 (6) , 679-680
- https://doi.org/10.1007/bf01970136
Abstract
The fibrinolytic inhibitor tranexamic acid affects certain experimental tumours; it prolongs survival (Lewis lung adenocarcinoma), decreases tumour weight (C3H breast carcinoma), and inhibits ascitic production (AH 130 rat hepatoma). However, it does not significantly influence DNA-synthesis in cell suspensions prepared from the same tumours.This publication has 25 references indexed in Scilit:
- Tumor growth inhibition mediated by trypsin inhibitor or urokinase inhibitorsPublished by Elsevier ,1978
- Fibrinolysis and antifibrinolytic drugs in the growth and spread of tumoursCancer Treatment Reviews, 1977
- Arrest of growth of ovarian tumor by tranexamic acidJAMA, 1977
- Treatment of Advanced Breast Cancer with Chemotherapeutics and Inhibition of Coagulation and FibrinolysisActa Medica Scandinavica, 1977
- Immunological identity of urokinase and ovarian carcinoma plasminogen activator released in tissue cultureNature, 1976
- Effect of proteolytic inhibitors on growth and surface architecture of normal and transformed cellsExperimental Cell Research, 1974
- PROPERTIES OF PLASMINOGEN ACTIVATORS FORMED BY NEOPLASTIC HUMAN CELL CULTURESThe Journal of Experimental Medicine, 1974
- THE CONVERSION OF C'1S TO C'1 ESTERASE BY PLASMIN AND TRYPSINThe Journal of Experimental Medicine, 1967
- Experimental and Clinical Studies on AMCA, the Antifibrinolytically Active Isomer of p‐Aminomethyl Cyclohexane Carboxylic AcidScandinavian Journal of Haematology, 1965